MoonLake Immunotherapeutics

Company Profile

MoonLake Immunotherapeutics had its IPO on 2020-10-20 under the ticker symbol MLTX.

The company operates in the Healthcare sector and Biotechnology industry. MoonLake Immunotherapeutics has a staff strength of 20 employees.

Stock update

Shares of MoonLake Immunotherapeutics opened at $62.26 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $57.55 - $62.69, and closed at $57.82.

This is a +9.88% increase from the previous day's closing price.

A total volume of 1,649,980 shares were traded at the close of the day’s session.

In the last one week, shares of MoonLake Immunotherapeutics have increased by +7.21%.

MoonLake Immunotherapeutics's Key Ratios

MoonLake Immunotherapeutics has a market cap of $2.88 billion, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months MoonLake Immunotherapeutics’s revenue was $0 with a gross profit of $0 and an EBITDA of $-57571224. The EBITDA ratio measures MoonLake Immunotherapeutics's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, MoonLake Immunotherapeutics’s operating margin was 0% while its return on assets stood at -11.9% with a return of equity of -18.79%.

In Q2, MoonLake Immunotherapeutics’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

MoonLake Immunotherapeutics’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.09 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into MoonLake Immunotherapeutics’s profitability.

MoonLake Immunotherapeutics stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

MoonLake Immunotherapeutics stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$506.62 million

Total Liabilities

$7.13 million

Operating Cash Flow

$12.68 million

Capital Expenditure

$0

Dividend Payout Ratio

0%

MoonLake Immunotherapeutics ended 2024 with $506.62 million in total assets and $0 in total liabilities. Its intangible assets were valued at $506.62 million while shareholder equity stood at $489.80 million.

MoonLake Immunotherapeutics ended 2024 with $0 in deferred long-term liabilities, $7.13 million in other current liabilities, 6245.00 in common stock, $-99794347.00 in retained earnings and $0 in goodwill. Its cash balance stood at $501.79 million and cash and short-term investments were $501.79 million. The company’s total short-term debt was $158,221 while long-term debt stood at $0.

MoonLake Immunotherapeutics’s total current assets stands at $506.37 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $619767.00 compared to accounts payable of $270754.00 and inventory worth $0.

In 2024, MoonLake Immunotherapeutics's operating cash flow was $12.68 million while its capital expenditure stood at $0.

Comparatively, MoonLake Immunotherapeutics paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$57.82

52-Week High

$63.4

52-Week Low

$6.9305

Analyst Target Price

$63.27

MoonLake Immunotherapeutics stock is currently trading at $57.82 per share. It touched a 52-week high of $63.4 and a 52-week low of $63.4. Analysts tracking the stock have a 12-month average target price of $63.27.

Its 50-day moving average was $55.04 and 200-day moving average was $28.57 The short ratio stood at 16.58 indicating a short percent outstanding of 0%.

Around 484.6% of the company’s stock are held by insiders while 6609.2% are held by institutions.